Jan. 27, 2022

BlueCross BlueShield of South Carolina and BlueChoice^® HealthPlan continue to monitor the status of the COVID-19 virus to ensure our provider community remains informed of any changes in policy or procedure related to the care of your patients, our members.

Remdesivir is an approved treatment drug for the COVID-19 virus that was originally allowed only in the inpatient place of service.  However, due to the recent surge in the number of COVID-19 cases as a result of the Omicron variant, the authorized use of this drug has been expanded to include the outpatient place of service.

Please note that prior authorization is not required for this outpatient service, and the member’s cost-share is dependent upon their benefit plan. This also includes the administration of the drug.

If you have any questions related to this bulletin, please contact Provider Education using the Provider Education Contact Form located on www.SouthCarolinaBlues.com or www.BlueChoiceSC.com.